Search

BiomX, a phage therapy biotech company, just announced that it's licensed new bacterial targets for commercialization of phage therapies for Primary Sclerosing Cholangitis (PSC; a rare, progressive liver disease). The targets: strains of Kl

ContraFect has received a $7.2 Million grant from the US Army Medical Research and Development Command to advance their engineered phage lysin candidate CF-296 for Staphylococcus aureus infections.

Intralytix announced that it will be collaborating with the Eliava Foundation and Ferring Pharmaceuticals to develop new phage-based drugs to improve reproductive medicine and women's health through modulation of the vaginal microbiome.

Dr. Darren Smith, Newcastle, UK The Hub for Biotechnology in the Built Environment (HBBE) is a £8M initiative between Northumbria and Newcastle Universities. HBBE will develop biotechnologies to create a new generation of buildings which ar

Intralytix announced that it will be collaborating with the Eliava Foundation and Ferring Pharmaceuticals to develop new phage-based drugs to improve reproductive medicine and women's health through modulation of the vaginal microbiome.

ContraFect has received a $7.2 Million grant from the US Army Medical Research and Development Command to advance their engineered phage lysin candidate CF-296 for Staphylococcus aureus infections.

Dr. Darren Smith, Newcastle, UK The Hub for Biotechnology in the Built Environment (HBBE) is a £8M initiative between Northumbria and Newcastle Universities. HBBE will develop biotechnologies to create a new generation of buildings which ar

BiomX, a phage therapy biotech company, just announced that it's licensed new bacterial targets for commercialization of phage therapies for Primary Sclerosing Cholangitis (PSC; a rare, progressive liver disease). The targets: strains of Kl

The business combination transaction between AmpliPhi and C3J, two phage therapy biotech companies, is expected to close today. The new name of the combined company will be Armata Pharmaceuticals, Inc., and shares will be expected to start

Phage Futures 2019 is next week! Even if you're not able to make it, we'll be posting tweets (#PhageFutures2019) and keeping you up to date on which speaker is speaking, what people's reactions are, and who's up next. Check out our Phage Fu

The business combination transaction between AmpliPhi and C3J, two phage therapy biotech companies, is expected to close today. The new name of the combined company will be Armata Pharmaceuticals, Inc., and shares will be expected to start

Micreos, a Dutch phage biotech company, secured 30 million Euro last month for its phage lysin technology. The company plans to use the funds for lysin development, and to launch its over-the-counter Gladskin product (anti-Staph aureus lysi

Micreos, a Dutch phage biotech company, secured 30 million Euro last month for its phage lysin technology. The company plans to use the funds for lysin development, and to launch its over-the-counter Gladskin product (anti-Staph aureus lysi

The phage therapy biotech company Ampliphi Biosciences is merging with C3J Therapeutics, a synthetic phage/antimicrobial engineering company.

Johnson & Johnson has invested $20 million (with another ~$800 million to follow if things go well) into Locus Biosciences, a biotech company equipping phages with CRISPR-Cas3 to obliterate bacterial DNA upon phage infection.

Bioharmony Therapeutics and Boehringer Ingelheim just announced a collaboration to develop Acinetobacter baumannii lysin therapeutics.

Great news for BiomX, a company developing custom phage therapies to treat microbiome-based diseases, which just raised $32 million in series B financing!

Listen to Dr. Minmin Yen, co-founder & CEO of the new biotech startup PhagePro, discuss her company's goals of preventing cholera with phages on the podcast "Important, Not Important". An especially great listen for grad students & postdocs

PhagoMed, a Vienna-based phage therapy company, was just awarded a Phoenix Award. The award honours young and successful companies that serve as role models for high-class research and entrepreneurship in Austria. Congratulations!

Listen to Dr. Minmin Yen, co-founder & CEO of the new biotech startup PhagePro, discuss her company's goals of preventing cholera with phages on the podcast "Important, Not Important". An especially great listen for grad students & postdocs